Home LiteratureArticle Details
PMID: 12101228 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.

Molecular and cellular biology ·Vol. 22 ·No. 15 ·2002-08-00 ·Pages 5319-36

Groulx I, Lee S

Abstract

It is becoming increasingly evident that the degradation of nuclear proteins requires nuclear-cytoplasmic trafficking of both the substrate proteins, as well as the E3 ubiquitin-ligases. Here, we show that nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein (VHL) is required for oxygen-dependent ubiquitination and degradation of the alpha subunits of hypoxia-inducible factor (HIF-alpha). VHL engages in a constitutive transcription-sensitive nuclear-cytoplasmic shuttle unaffected by oxygen tension or levels of nuclear substrate HIF-alpha. Ubiquitinated forms of HIF-alpha, as well as VHL/ubiquitinated HIF-alpha complexes, are found solely in the nuclear compartment of normoxic or reoxygenated VHL-competent cells. HIF-alpha localizes exclusively in the nucleus of hypoxic cells but is exported to the cytoplasm upon reoxygenation. Oxygen-dependent nuclear ubiquitination and nuclear export of HIF-alpha can be prevented by treatment with an HIF-specific prolyl hydroxylase inhibitor. Treatment with inhibitors of RNA polymerase II activity, which interfere with the ability of VHL to engage in nuclear export, also prevents cytoplasmic accumulation of HIF-alpha in reoxygenated cells. This caused a marked increase in the HIF-alpha half-life without affecting its nuclear ubiquitination. We present a model by which VHL-mediated ubiquitination of HIF-alpha and its subsequent degradation are dependent upon dynamic nuclear-cytoplasmic trafficking of both the E3 ubiquitin-ligase and the nuclear substrate protein.

MeSH Terms
Active Transport, Cell Nucleus/drug effects,physiology Animals Blotting, Western Cell Compartmentation/physiology Cell Hypoxia/physiology Cell Line Cell Nucleus/metabolism Cytoplasm/metabolism Enzyme Inhibitors/pharmacology Fatty Acids, Unsaturated/pharmacology Fibroblasts/cytology,drug effects,metabolism Green Fluorescent Proteins HeLa Cells Humans Hypoxia-Inducible Factor 1, alpha Subunit Ligases/metabolism Luminescent Proteins/genetics Mice Oxygen/metabolism Procollagen-Proline Dioxygenase/antagonists & inhibitors RNA Polymerase II/antagonists & inhibitors Recombinant Fusion Proteins/genetics,metabolism Transcription Factors/genetics,metabolism Tumor Suppressor Proteins Ubiquitin/metabolism Ubiquitin-Protein Ligases Von Hippel-Lindau Tumor Suppressor Protein
Chemicals
Enzyme Inhibitors Fatty Acids, Unsaturated HIF1A protein, human Hypoxia-Inducible Factor 1, alpha Subunit Luminescent Proteins Recombinant Fusion Proteins Transcription Factors Tumor Suppressor Proteins Ubiquitin Green Fluorescent Proteins Procollagen-Proline Dioxygenase Ubiquitin-Protein Ligases Von Hippel-Lindau Tumor Suppressor Protein RNA Polymerase II Ligases VHL protein, human Oxygen leptomycin B
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Groulx Isabelle
Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, K1H 8M5 Ontario, Canada.
Lee Stephen
References (67)
67 references, click to expand
  1. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
    Mol Cell Biol. 1998 Dec;18(12):7288-93 PMID: 9819415
  2. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha.
    Gene Expr. 1998;7(3):205-13 PMID: 9840812
  3. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
    Mol Cell Biol. 1999 Feb;19(2):1289-300 PMID: 9891063
  4. A conserved family of prolyl-4-hydroxylases that modify HIF.
    Science. 2001 Nov 9;294(5545):1337-40 PMID: 11598268
  5. A new technique for the assay of infectivity of human adenovirus 5 DNA.
    Virology. 1973 Apr;52(2):456-67 PMID: 4705382
  6. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  7. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Nature. 1993 Apr 29;362(6423):857-60 PMID: 8479525
  8. Identification of the von Hippel-Lindau disease tumor suppressor gene.
    Science. 1993 May 28;260(5112):1317-20 PMID: 8493574
  9. Mutations of the VHL tumour suppressor gene in renal carcinoma.
    Nat Genet. 1994 May;7(1):85-90 PMID: 7915601
  10. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.
    JAMA. 1995 Feb 15;273(7):564-70 PMID: 7837390
  11. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
    Hum Mol Genet. 1994 Dec;3(12):2169-73 PMID: 7881415
  12. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.
    Hum Mutat. 1995;5(1):66-75 PMID: 7728151
  13. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
    Mol Cell Biol. 1999 Feb;19(2):1486-97 PMID: 9891082
  14. Moving protein heads for breakdown.
    Nature. 1999 Mar 11;398(6723):103-4 PMID: 10086352
  15. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.
    Nature. 1999 Mar 11;398(6723):160-5 PMID: 10086358
  16. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
    Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12436-41 PMID: 10535940
  17. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2.
    J Biol Chem. 2000 Mar 24;275(12):8991-9000 PMID: 10722748
  18. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Nat Cell Biol. 2000 Jul;2(7):423-7 PMID: 10878807
  19. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.
    Cancer Res. 2000 Aug 1;60(15):4010-5 PMID: 10945599
  20. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    J Biol Chem. 2000 Aug 18;275(33):25733-41 PMID: 10823831
  21. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    EMBO J. 2000 Aug 15;19(16):4298-309 PMID: 10944113
  22. HIF-1 and human disease: one highly involved factor.
    Genes Dev. 2000 Aug 15;14(16):1983-91 PMID: 10950862
  23. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5 PMID: 10973499
  24. Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4.
    EMBO J. 2000 Nov 15;19(22):6085-97 PMID: 11080155
  25. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation.
    FEBS Lett. 2001 Feb 23;491(1-2):85-90 PMID: 11226425
  26. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    J Biol Chem. 2001 Jan 12;276(2):1407-16 PMID: 11024059
  27. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver.
    Biochem J. 2001 Mar 15;354(Pt 3):531-7 PMID: 11237857
  28. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
    Science. 2001 Apr 20;292(5516):464-8 PMID: 11292862
  29. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Science. 2001 Apr 20;292(5516):468-72 PMID: 11292861
  30. Induction of HIF-1alpha in response to hypoxia is instantaneous.
    FASEB J. 2001 May;15(7):1312-4 PMID: 11344124
  31. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines.
    Clin Cancer Res. 2001 May;7(5):1263-72 PMID: 11350893
  32. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins.
    Mol Biol Cell. 2001 May;12(5):1431-43 PMID: 11359933
  33. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm.
    EMBO Rep. 2001 Jul;2(7):615-20 PMID: 11454738
  34. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1.
    Mol Cell Biol. 2001 Aug;21(16):5396-407 PMID: 11463822
  35. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.
    Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5 PMID: 11504942
  36. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
    EMBO J. 2001 Sep 17;20(18):5197-206 PMID: 11566883
  37. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha.
    Biochem Biophys Res Commun. 2001 Oct 5;287(4):808-13 PMID: 11573933
  38. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.
    Cell. 2001 Oct 5;107(1):43-54 PMID: 11595184
  39. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Exp Cell Res. 2001 Oct 15;270(1):66-77 PMID: 11597128
  40. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
    Oncogene. 1999 Feb 25;18(8):1529-35 PMID: 10102622
  41. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.
    Science. 1999 Apr 16;284(5413):455-61 PMID: 10205047
  42. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
    Science. 1999 Apr 23;284(5414):657-61 PMID: 10213691
  43. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Nature. 1999 May 20;399(6733):271-5 PMID: 10353251
  44. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.
    Genes Dev. 1999 Jul 15;13(14):1822-33 PMID: 10421634
  45. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein.
    Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9533-8 PMID: 10449727
  46. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export.
    J Biol Chem. 1999 Oct 1;274(40):28708-15 PMID: 10497241
  47. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
    Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6459-63 PMID: 7604013
  48. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.
    Cell. 1995 Aug 11;82(3):475-83 PMID: 7543368
  49. Inhibition of transcription elongation by the VHL tumor suppressor protein.
    Science. 1995 Sep 8;269(5229):1402-6 PMID: 7660122
  50. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
    Science. 1995 Sep 8;269(5229):1444-6 PMID: 7660130
  51. Tumour suppression by the human von Hippel-Lindau gene product.
    Nat Med. 1995 Aug;1(8):822-6 PMID: 7585187
  52. Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm.
    Virology. 1995 Nov 10;213(2):439-49 PMID: 7491768
  53. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Mol Med. 1995 Jan;1(2):142-52 PMID: 8529093
  54. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.
    Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10 PMID: 8603073
  55. p53: puzzle and paradigm.
    Genes Dev. 1996 May 1;10(9):1054-72 PMID: 8654922
  56. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
    Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1770-5 PMID: 8700833
  57. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit.
    J Biol Chem. 1996 Dec 13;271(50):32253-9 PMID: 8943284
  58. p53, the cellular gatekeeper for growth and division.
    Cell. 1997 Feb 7;88(3):323-31 PMID: 9039259
  59. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2156-61 PMID: 9122164
  60. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre.
    Somat Cell Mol Genet. 1996 Nov;22(6):477-88 PMID: 9131017
  61. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.
    J Biol Chem. 1997 Sep 5;272(36):22642-7 PMID: 9278421
  62. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
    EMBO J. 1998 Jan 15;17(2):554-64 PMID: 9430646
  63. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.
    Mol Cell Biol. 1998 Feb;18(2):732-41 PMID: 9447969
  64. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 PMID: 9653127
  65. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8817-22 PMID: 9671762
  66. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
    Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11661-6 PMID: 9751722
  67. The ubiquitin system.
    Annu Rev Biochem. 1998;67:425-79 PMID: 9759494
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
2002-08-00
Pages
5319-36
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC133938
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com